Therefore, both increased HIF-α stability (by PHD inhibition) and enhanced HIF-α transcriptional activity (by FIH inhibition) are desirable to elicit a strong therapeutic effect against AML, which can be further potentiated by venetoclax. Here, CASR is linked to acute myeloid leukemia.